TraceLink grows market position in DACH region by 215%

13 Mar 2018

Customers cite network connectivity, efficiency of partner onboarding, and seamless data exchange as significant differentiators.

TraceLink has announced 215% customer growth in the DACH region (Germany, Austria and Switzerland) for 2017.

TraceLink grows market position in DACH region by 215%

Now serving over 40 customers in the region, TraceLink experienced a 138% growth in revenues from its German, Austrian and Swiss customers in 2017. To meet demand for its expanding DACH customer base, TraceLink has grown its European team by 169%, currently employing 22 native German-speaking team members.

To counter the threat of falsified medicines entering the legal supply chain, companies who manufacture, sell or dispense medications in the European Union must comply with track and trace regulations outlined in the Falsified Medicines Directive (FMD), including serialization, compliance reporting and verification requirements, by February 2019. Characterized by a strong community of small- and mid-sized life sciences organizations, in addition to several domestic large pharmaceutical companies, the DACH region represents a core area in the European market with a significant need for serialization and compliance with the EU FMD.

What DACH Customers and Partners Are Saying

Ortwin Kottwitz, CEO of Germany-based biotech and TraceLink customer, biosyn said: “We have customers and partners located all over the world and could not afford to lose time and resources by establishing individual point-to-point connections. After a thorough evaluation of solution providers, it was clear that TraceLink’s network approach would deliver the scalability we needed while providing a simple and fast connection into the EU Hub.”

Michael Unbehaun, manager engineering projects at R-Pharm Germany, a TraceLink partner, explained: “As a contract manufacturer, we need to be able to connect to multiple customers, managing and sharing data securely and efficiently. By accessing the TraceLink Life Sciences Cloud we can facilitate EU FMD compliance for our customers who supply markets in Europe. The simplicity of the solution, together with our proactive approach, has helped our customers achieve compliance ahead of the regulatory deadline.”

Boris Brunow of Switzerland-based contract packaging organization (CPO) Allpack, a TraceLink customer, said: “Our partnership with TraceLink has allowed us to manage and exchange serialization data more efficiently by eliminating outdated data transfer processes and simplifying the onboarding process for our customers. We evaluated potential partners over a 2-year period, eventually selecting TraceLink for its network approach, as well as its specialist focus in the pharma sector.”

“The EU FMD deadline is now less than a year away, requiring businesses to begin actively preparing for their serialization and regulatory requirements now. Over 190 companies are already serializing with TraceLink and with more than 265,000 partners on our network, we are well positioned to serve the growing number of companies of all sizes in Germany, Austria and Switzerland,” said Shabbir Dahod, president and CEO, TraceLink. “On an organizational level, we now have more employees dedicated to serving the DACH region than some of our competitors have for total number of employees, giving TraceLink a distinct advantage in our ability to service the specific needs of pharmaceutical and contract manufacturers across the region.”

To support companies’ compliance and serialization challenges in both the DACH region and across Europe, TraceLink is hosting FutureLink in Munich from 5–7 June 2018. FutureLink is the industry’s largest annual gathering of commercial and operational executives from the pharmaceutical and healthcare industries. The conference provides distinct learning forums for a range of business leaders to develop strategies that address rapidly approaching compliance deadlines — and to discuss the analog-to-digital information-sharing transformation taking place in the pharmaceutical and healthcare industries.

Read More

Related news

One month on: medical cannabis is still taboo despite change in law

One month on: medical cannabis is still taboo despite change in law

11 Dec 2018

Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.

Read more 
EU FMD - time is running out!

EU FMD - time is running out!

13 Nov 2018

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

Read more 
Proprietary nasal delivery formulation of diazepam reaches NDA

Proprietary nasal delivery formulation of diazepam reaches NDA

7 Nov 2018

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

Read more 
DSCSA one-month countdown!

DSCSA one-month countdown!

30 Oct 2018

With only a month to go, it really is too late to start trying to develop an in-house solution.

Read more 
Global pharma set for strong year

Global pharma set for strong year

23 Oct 2018

Eight of the top ten pharma nations reporting improving market conditions.

Read more 
Generics companies to move away from little white pills

Generics companies to move away from "little white pills"

14 Oct 2018

Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.

Read more 
CMOs to benefit from double digit approvals for ADCs in the next 3 years

CMOs to benefit from double digit approvals for ADCs in the next 3 years

9 Oct 2018

Therapeutic ADC market expected to reach $4 billion by 2023.

Read more 
Movement on the market reflected at CPhI Worldwide 2018

Movement on the market reflected at CPhI Worldwide 2018

3 Oct 2018

Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

Read more 
Sanofi to refocus two global business units

Sanofi to refocus two global business units

19 Sep 2018

The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

Read more 
Moulds & Tooling: A European success story

Moulds & Tooling: A European success story

19 Sep 2018

While not quite an endangered species, the past fifteen years have not been easy ones for many European mould makers. Many, but not all, and IGS GeboJagema is a case in point – a case that shows the difference automation and focus can make. By Karen La...

Read more